RT Journal Article
T1 Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report.
A1 Martinez-Montoro, Jose Ignacio
A1 Pinzon-Martín, Jose Luis
A1 Damas-Fuentes, Miguel
A1 Fernandez-Valero, Andrea
A1 Tinahones, Francisco J
K1 Type A insulin resistance syndrome
K1 diabetes
K1 glucagon-like peptide-1 receptor agonist
K1 insulin resistance
K1 sodium-glucose cotransporter 2 inhibitor
AB Type A insulin resistance (IR) syndrome is a very uncommon genetic disorder affecting the insulin receptor (INSR) gene, characterized by severe IR without the presence of obesity. Patients with this condition will eventually develop diabetes, presenting a variable response to insulin-sensitizers, such as metformin and thiazolidinediones, and high doses of insulin. We report for the first time the results of the use of combination therapy with a glucagon-like peptide-1 receptor agonist and a sodium-glucose cotransporter 2 inhibitor for the treatment of diabetes in the context of type A IR syndrome.
PB Frontiers
SN 1664-2392
YR 2022
FD 2022-03-07
LK http://hdl.handle.net/10668/20559
UL http://hdl.handle.net/10668/20559
LA en
NO Martínez-Montoro JI, Pinzón-Martín JL, Damas-Fuentes M, Fernández-Valero A, Tinahones FJ. Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report. Front Endocrinol (Lausanne). 2022 Apr 14;13:838887
DS RISalud
RD Apr 6, 2025